Review: Atenolol may be ineffective for reducing cardiovascular morbidity or all-cause mortality in primary hypertension: COMMENTARY

Cruickshank, J. Kennedy
May 2005
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p59
Academic Journal
The article comments on the study on cardiovascular morbidity in primary hypertension. Preliminary results from the large ASCOT open-label trial were recently presented to the American College of Cardiology Annual Scientific Session (3); some 19 000 higher-risk patients with hypertension were randomized to atenolol 50 to 100 mg, then bendrofluazide 1.25 to 2.5 mg if needed, or to amlodipine 5 to 10 mg, then perindopril 4 to 8 mg per day if needed. In summary, the meta-analysis by researchers and newer data suggest that atenolol, when used as first-line therapy for hypertension, is inferior to several other medications.


Related Articles

  • Independent Nurse: Study data questions the value of atenolol.  // GP: General Practitioner;6/17/2005, p72 

    The article informs that atenolol is no better than placebo for reducing cardiovascular morbidity in patients with hypertension. Researchers analysed data from four randomised controlled trials involving 6,825 patients, comparing atenolol with placebo or no treatment and found that the groups...

  • Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients. Odili, Augustine N; Ezeala-Adikaibe, Birinus; Ndiaye, Mouhamadou B; Anisiuba, Benedict C; Kamdem, Marius M; Ijoma, Chinwuba K; Kaptue, Joseph; Boombhi, Hilaire J; Kolo, Philip M; Shu, Elvis N; Thijs, Lutgarde; Stassen, Jan A; Omotoso, Babatunde A; Kingue, Samuel; Ba, Serigne A; Lemogoum, Daniel; M'Buyamba-Kabangu, Jean-René; Ulasi, Ifeoma I // Trials;2012, Vol. 13 Issue 1, p59 

    Background: The epidemic surge in hypertension in sub-Saharan Africa is not matched by clinical trials of antihypertensive agents in Black patients recruited in this area of the world. We mounted the Newer versus Older Antihypertensive agents in African Hypertensive patients (NOAAH) trial to...

  • Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention. Fretheim, Atle; Oxman, Andrew D.; Håvelsrud, Kari; Treweek, Shaun; Kristoffersen, Doris T.; Bjørndal, Arild; Håvelsrud, Kari; Bjørndal, Arild // PLoS Medicine;Jun2006, Vol. 3 Issue 6, pe134 

    Background: A gap exists between evidence and practice regarding the management of cardiovascular risk factors. This gap could be narrowed if systematically developed clinical practice guidelines were effectively implemented in clinical practice. We evaluated the effects of a...

  • Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome? Karagiannis, Asterios; Mikhailidis, Dimitri P.; Kakafika, Anna I.; Tziomalos, Konstantinos; Athyros, Vasilios G. // Current Pharmaceutical Design;Jan2007, Vol. 13 Issue 2, p229 

    The beneficial effect of antihypertensive treatment on the risk of major vascular events is well established. Several trials comparing older and newer drugs in the treatment of primary hypertension suggested that it is the blood pressure achieved, rather than choice of the drug that determines...

  • Amlodipine/perindopril improves outcomes vs atenolol/diuretic.  // Formulary;Oct2005, Vol. 40 Issue 10, p345 

    Reports that an antihypertensive regimen of amlodipine with added perindropil significantly reduces all-cause mortality and most major adverse cardiovascular outcomes compared with a regimen of atenolol with the addition of a diuretic. Final results of the Anglo-Scandinavian Cardiac Outcomes...

  • Review: Drugs for mild-to-moderate hypertension in pregnancy reduce risk for severe hypertension but not preeclampsia: COMMENTARY. Magee, Laura A. // ACP Journal Club;Jul/Aug2007, Vol. 147 Issue 1, p9 

    The author reflects on a study, conducted by E. Abalos and colleagues, which focuses on the benefits and risks of antihypertensive (anti-HT) drugs in pregnant women with mild-to-moderate hypertension. She opines that the study provides no evidence that anti-HT agents are likely to decrease the...

  • CORRECTIONS.  // JAMA: Journal of the American Medical Association;5/11/2011, Vol. 305 Issue 18, p1862 

    Corrections to the articles "Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer" that was published in the December 1, 2010 issue and "Antihypertensive Treatment and Secondary Prevention of Cardioavascular Disease Events Among Persons Without Hypertension:...

  • Treatment of hypertension. Newson, Louise // GP: General Practitioner;8/4/2006, p30 

    The article presents the author's views regarding the treatment of hypertension which is the most common treatable risk factor for cardiovascular disease in the over-50s. It has been found in a meta-analysis that beta-blockers do not protect people from stroke. It has been recommended in the...

  • Antihypertensive Properties of Plant-Based Prebiotics. Siok-Koon Yeo; Lay-Gaik Ooi; Ting-Jin Lim; Min-Tze Liong // International Journal of Molecular Sciences;Aug2009, Vol. 10 Issue 8, p3517 

    Hypertension is one of the major risk factors for cardiovascular disease. Although various drugs for its treatment have been synthesized, the occurring side effects have generated the need for natural interventions for the treatment and prevention of hypertension. Dietary intervention such as...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics